Evogene (NASDAQ:EVGN) vs. Mirum Pharmaceuticals (NASDAQ:MIRM) Head-To-Head Survey

Evogene (NASDAQ:EVGN) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

Valuation and Earnings

This table compares Evogene and Mirum Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evogene	$3.85 million	0.82	-$8.48 million	($0.91)	-0.40
Mirum Pharmaceuticals	$521.31 million	11.69	-$23.36 million	($15.47)	-6.03

Evogene has higher earnings, but lower revenue than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Evogene, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Evogene and Mirum Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evogene	-694.18%	-156.53%	-86.80%
Mirum Pharmaceuticals	-134.75%	-97.25%	-12.59%

Insider and Institutional Ownership

10.4% of Evogene shares are held by institutional investors. 7.4% of Evogene shares are held by insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Evogene and Mirum Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evogene	1	0	0	0	1.00
Mirum Pharmaceuticals	1	0	13	1	2.93

Mirum Pharmaceuticals has a consensus price target of $155.56, suggesting a potential upside of 66.68%. Given Mirum Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than Evogene.

Volatility & Risk

Evogene has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500.

Summary

Mirum Pharmaceuticals beats Evogene on 10 of the 14 factors compared between the two stocks.

About Evogene

Evogene Ltd. (NASDAQ: EVGN) is an Israel-based computational biology company that develops technologies and products designed to improve human health, agriculture and sustainability. The company uses artificial intelligence, machine learning and biological data analysis through its Computational Predictive Biology platform to identify and develop solutions based on biological mechanisms. Evogene has built a portfolio of subsidiaries and business units focused on areas including agricultural biologicals, crop protection, microbiome-based therapeutics and medical cannabis.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare liver and other serious diseases. Founded in 2018, the company works on therapies for conditions with limited treatment options. Its commercial products include Livmarli (maralixibat), an oral treatment for cholestatic pruritus associated with Alagille syndrome and, in the United States, progressive familial intrahepatic cholestasis. Mirum also markets Cholbam (cholic acid) for certain bile acid synthesis disorders and Chenodal (chenodiol) for cerebrotendinous xanthomatosis.